Vernalis, Endo Pharma Say U.S. FDA Gives Frova New Target Action Date of Sept. 30

Vernalis and Endo Pharmaceuticals Inc said the U.S. Food and Drug Administration is targeting Sept. 30 as the date for issuing an action letter for the supplemental New Drug Application (sNDA) for Frova 2.5 mg tablets.
Hemscott